Pre-earnings options volume in Summit Therapeutics (SMMT) is normal with calls leading puts 10:7. Implied volatility suggests the market is anticipating a move near 6.7%, or $1.66, after results are released. Median move over the past eight quarters is 13.4%.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SMMT:
- Is SMMT a Buy, Before Earnings?
- Summit Therapeutics selloff Friday on data overdone, says H.C. Wainwright
- Summit Therapeutics Receives Buy Rating Amid Promising Ivonescimab Developments and Strategic Trials
- BMO says Keytruda ‘still reigns’ after ivonescimab survival data
- Citi says buy Summit amid ‘significant market confusion’